Physician profile
Michael Yen
NPI 1356315907
$1,312.92
in general payments reported to CMS, 2019-2025
22 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $127 · 2021: $41.10 · 2022: $18.54 · 2023: $178 · 2024: $150 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $173.26 | 2019-2021 | |
| Boston Scientific Corporation | $163.67 | 2019-2025 | General - Vascular Access, Avvigo Guidance System |
| Abiomed | $142.25 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $140.72 | 2022-2024 | |
| Cardiovascular Systems INC. | $97.14 | 2019-2021 | |
| Medtronic Vascular, INC. | $89.44 | 2019 | |
| Horizon Therapeutics Plc | $64.75 | 2020 | |
| Inari Medical, INC. | $59.85 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $49.92 | 2019 | |
| Amgen INC. | $49.33 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.10 | 2019 | |
| Biosense Webster, INC. | $39.50 | 2023 | Octaray Mapping Catheter |
| Cook Medical LLC | $27.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.83 | 2019 | |
| Abbott Laboratories | $21.62 | 2025 | Cardiomems |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.88 | 2019 | |
| Novo Nordisk INC | $20.18 | 2023 | Saxenda, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $19.95 | 2024 | Arcalyst |
| Medtronic, INC. | $17.62 | 2023 | Micra |
| Sanofi-Aventis U.S. LLC | $15.22 | 2019 | |
| Pfizer INC. | $14.69 | 2019 | |
| Edwards Lifesciences Corporation | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.